Published in Maturitas on September 27, 2013
Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases. J Immunol Res (2015) 0.93
Risk factors for osteoporosis in inflammatory bowel disease patients. World J Gastrointest Pathophysiol (2015) 0.80
Managing osteoporosis in ulcerative colitis: something new? World J Gastroenterol (2014) 0.80
BMI and BMD: The Potential Interplay between Obesity and Bone Fragility. Int J Environ Res Public Health (2016) 0.79
Osteoprotegerin, s-RANKL, and selected interleukins in the pathology of bone metabolism in patients with Crohn's disease. Prz Gastroenterol (2015) 0.75
Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease: A meta-analysis. Medicine (Baltimore) (2017) 0.75
Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. Medicine (Baltimore) (2017) 0.75
Diversity of the human intestinal microbial flora. Science (2005) 49.64
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA (2006) 6.26
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
How many duodenal biopsy specimens are required to make a diagnosis of celiac disease? Gastrointest Endosc (2008) 4.58
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology (2010) 3.87
Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ (2008) 3.31
Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol (2010) 3.12
Rate and predictors of early/missed colorectal cancers after colonoscopy in Manitoba: a population-based study. Am J Gastroenterol (2010) 2.97
Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol (2003) 2.63
Frequency of colorectal cancer screening and the impact of family physicians on screening behaviour. CMAJ (2007) 2.60
Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol (2007) 2.46
High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut (2006) 2.43
Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol (2009) 2.36
Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol (2011) 2.32
Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis (2011) 2.31
Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res (2011) 2.24
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24
Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol (2009) 2.22
Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology (2011) 2.22
Using multiple data features improved the validity of osteoporosis case ascertainment from administrative databases. J Clin Epidemiol (2008) 2.19
AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology (2003) 2.17
Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis (2009) 2.15
Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J (2005) 2.15
Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol (2009) 2.05
Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol (2008) 2.04
The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 1.92
Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol (2008) 1.92
AGA technical review on osteoporosis in hepatic disorders. Gastroenterology (2003) 1.89
Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res (2014) 1.86
Geographical variability and environmental risk factors in inflammatory bowel disease. Gut (2013) 1.84
Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol (2009) 1.83
World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis (2010) 1.82
FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res (2012) 1.82
Low bone mineral density and fracture burden in postmenopausal women. CMAJ (2007) 1.81
Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol (2003) 1.80
Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol (2012) 1.73
The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol (2008) 1.72
Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.63
5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol (2012) 1.61
Pathological reassessment of hyperplastic colon polyps in a city-wide pathology practice: implications for polyp surveillance recommendations. Gastrointest Endosc (2012) 1.60
Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada (summary). CMAJ (2010) 1.59
Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology (2009) 1.59
Colonoscopy and its complications across a Canadian regional health authority. Gastrointest Endosc (2009) 1.56
Relationship Among Body Fat Percentage, Body Mass Index, and All-Cause Mortality: A Cohort Study. Ann Intern Med (2016) 1.56
A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res (2014) 1.56
WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet (2012) 1.55
The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol (2006) 1.52
Role of biological therapy for inflammatory bowel disease in developing countries. Gut (2011) 1.51
Crohn's disease recurrence in a small bowel transplant. Am J Gastroenterol (2004) 1.49
Bone density in a population-based cohort of premenopausal adult women with early onset inflammatory bowel disease. Am J Gastroenterol (2003) 1.48
Therapy insight: Osteoporosis in inflammatory bowel disease--advances and retreats. Nat Clin Pract Gastroenterol Hepatol (2005) 1.48
Sexual abuse in irritable bowel syndrome: to ask or not to ask -- that is the question. Can J Gastroenterol (2002) 1.47
Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ (2010) 1.45
The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study. J Rheumatol (2013) 1.44
First-degree relatives of patients with rheumatoid arthritis exhibit high prevalence of joint symptoms. J Rheumatol (2013) 1.44
Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis (2010) 1.43
A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period. Am J Gastroenterol (2009) 1.43
The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol (2012) 1.42
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
Brain-gut interactions in inflammatory bowel disease. Gastroenterology (2012) 1.42
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol (2013) 1.36
A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues. Am J Epidemiol (2006) 1.33
A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.32
Recognizing and reporting vertebral fractures: reducing the risk of future osteoporotic fractures. Can Assoc Radiol J (2007) 1.32
Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.30
AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem Pharmacol (2010) 1.29
FRAX(®) with and without bone mineral density. Calcif Tissue Int (2011) 1.29
Health care resource utilization in inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 1.28
Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res (2007) 1.28
Canadian Aboriginal women have a higher prevalence of vitamin D deficiency than non-Aboriginal women despite similar dietary vitamin D intakes. J Nutr (2007) 1.27
Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology (2011) 1.24
Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis. Inflamm Bowel Dis (2010) 1.22
10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program. Arch Intern Med (2008) 1.20
Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr (2007) 1.20
Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol (2006) 1.20
Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom (2004) 1.18
The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol (2003) 1.17
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol (2009) 1.15
Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom (2007) 1.15
Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clin Gastroenterol Hepatol (2006) 1.15
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14
Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2009) 1.14
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
The evolving epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol (2009) 1.13
Postfracture care for older women: gaps between optimal care and actual care. Can Fam Physician (2008) 1.11
Osteoporosis-related fracture case definitions for population-based administrative data. BMC Public Health (2012) 1.11
Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J (2011) 1.11
A population-based case-control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis. Am J Gastroenterol (2006) 1.10
Socioeconomic status and the utilization of diagnostic imaging in an urban setting. CMAJ (2005) 1.09
Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions. Inflamm Bowel Dis (2008) 1.09
Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis Rheum (2012) 1.09
Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. Am J Gastroenterol (2011) 1.09
The incidence of Helicobacter pylori acquisition in children of a Canadian First Nations community and the potential for parent-to-child transmission. Helicobacter (2004) 1.07
Fracture risk in living kidney donors: a matched cohort study. Am J Kidney Dis (2012) 1.06
Time trends in colon cancer incidence and distribution and lower gastrointestinal endoscopy utilization in Manitoba. Am J Gastroenterol (2008) 1.06